See more : Almirall, S.A. (LBTSF) Income Statement Analysis – Financial Results
Complete financial analysis of Sagaliam Acquisition Corp. (SAGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sagaliam Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Hyoki Kaiun Kaisha, Ltd. (9362.T) Income Statement Analysis – Financial Results
- Scorpio Gold Corporation (SRCRF) Income Statement Analysis – Financial Results
- ArcelorMittal S.A. (ARRD.DE) Income Statement Analysis – Financial Results
- Raffles Interior Limited (1376.HK) Income Statement Analysis – Financial Results
- Shandong Intco Recycling Resources Co., Ltd. (688087.SS) Income Statement Analysis – Financial Results
Sagaliam Acquisition Corp. (SAGA)
About Sagaliam Acquisition Corp.
Sagaliam Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the telecommunications, media, and technology industries. The company was incorporated in 2021 and is based in Los Angeles, California.
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 4.57M | 0.00 |
| Gross Profit | -4.57M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 240.00K | 213.33 |
| Selling & Marketing | 0.00 | 170.59K |
| SG&A | 240.00K | 170.81K |
| Other Expenses | 4.68M | -150.00K |
| Operating Expenses | 4.92M | 320.81K |
| Cost & Expenses | 4.92M | 320.81K |
| Interest Income | 1.51M | 9.36 |
| Interest Expense | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 7.02K |
| EBITDA | -4.92M | -320.81K |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -4.92M | -320.81K |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.51M | 7.02K |
| Income Before Tax | -3.41M | -313.79K |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | -1.51M | -7.02K |
| Net Income | -1.90M | -313.79K |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -0.44 | -0.02 |
| EPS Diluted | -0.44 | -0.02 |
| Weighted Avg Shares Out | 4.35M | 14.89M |
| Weighted Avg Shares Out (Dil) | 4.35M | 14.89M |
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the...
SAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER
New York, NY, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, “SAGAR”) (“we”, “us”, “our”, or the “Company”) announced today that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq...
Biogenysis' International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation Treaty (PCT) application covering its inventions relating to Anti-SARS-CoV-2 Monoclonal...
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
Reports on Business combination agreement progress ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced...
SAGALIAM ACQUISITION CORP. CONFIRMS FUNDING AND EXTENSION OF DEADLINE TO COMPLETE BUSINESS COMBINATION
New York, NY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, “SAGAR”) (“we”, “us”, “our”, or the “Company”) announced today that it was exercising its option to extend the time available to consummate its business combination...
SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER AND APPOINTMENT OF INDEPENDENT DIRECTORS
New York, NY, July 28, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, “SAGAR”) (“we”, “us”, “our”, or the “Company”) announced today that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq...
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. ("ENZC" or the "Company") filed a Supplemental Information report today to provide additional details regarding the recently entered non-binding letter of intent with...
Source: https://incomestatements.info
Category: Stock Reports